ArticleRheumatology international2020
Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19.
Article in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders.European journal of pediatrics · 2023Review
- COVID-19 in immunocompromised children and adolescents.Clinical and experimental pediatrics · 2023Article
- Rapid Review of Medication Taking (Adherence) Among Patients With Rheumatic Diseases During the COVID-19 Pandemic.Arthritis care & research · 2022Article
- Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry.Rheumatology (Oxford, England) · 2022Article
- Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis.International journal of molecular sciences · 2022Review
- Different Course of SARS-CoV-2 Infection in Two Adolescents With Other Immunosuppressive Factors.Cureus · 2022Article
- Impact of COVID-19 Pandemic on Patients with Rheumatic and Musculoskeletal Diseases: Disruptions in Care and Self-Reported Outcomes.Journal of patient experience · 2022Article
- Optimal biologics for juvenile idiopathic arthritis in an infection with SARS-CoV-2 α-variant.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022Article
- Impact of COVID-19 on Pediatric Immunocompromised Patients.Pediatric clinics of North America · 2021Review
- SARS-CoV-2 infection in children with rheumatic disease: Experience of a tertiary referral center.Archives of rheumatology · 2021Article
- Article
- Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases.Pediatric rheumatology online journal · 2021Article
- Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study.Journal of clinical medicine · 2021Article
- COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy.International journal of environmental research and public health · 2021Review
- COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment.Journal of clinical medicine · 2021Article
- Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends.Rheumatology international · 2021Observational
- Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.Journal of the neurological sciences · 2021Article
- COVID-19 in Immunosuppressed Children.Frontiers in pediatrics · 2021Review
- Reporting Survey Based Studies - a Primer for Authors.Journal of Korean medical science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The aim of the research was to further extend current knowledge of whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19) entails a risk for children with various rheumatic diseases under immunosuppressive treatment. Telephone survey was administered by conducting interviews with the parents from May 1, 2020 to May 20, 2020. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments. Patients who were followed-up under immunosuppressive treatment (n = 439) were attempted to be contacted. The diagnostic distribution of patients (n = 414) eligible for the study was as follows: juvenile idiopathic arthritis (JIA) (n = 243, 58.7%), autoinflammatory diseases (n = 109, 26.3%), connective tissue diseases (n = 51, 12.3%), and vasculitis (n = 11, 2.7%). In the entire cohort, the mean age was 12 ± 4.7 years, and 54.1% (n = 224) were female. Nine patients have attended the hospital for COVID-19 evaluation, 6 of whom were in close contact with confirmed cases. One patient with seronegative polyarticular JIA, previously prescribed methotrexate and receiving leflunomide during pandemic was identified to be diagnosed with COVID-19. None, including the confirmed case, had any severe symptoms. More than half of the patients with household exposure did not require hospitalization as they were asymptomatic. Although circumstances such as compliance in social distancing policy, transmission patterns, attitude following contact may have influenced the results, immunosuppressive treatment does not seem to pose an additional risk in terms of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.